Summary

Persistence Market Research has recently released a comprehensive report on the global Alzheimer’s Disease Diagnostics and Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Alzheimer’s Disease Diagnostics and Treatment Market Size (2025E): US$ 7.72 Bn
• Projected Market Value (2032F): US$ 14.14 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 9.0%

Alzheimer’s Disease Diagnostics and Treatment Market - Report Scope:

The Alzheimer’s disease diagnostics and treatment market encompasses a wide range of solutions aimed at early detection, monitoring, and therapeutic management of Alzheimer’s disease. This includes diagnostic technologies such as cerebrospinal fluid (CSF) tests, blood-based biomarkers, brain imaging, and cognitive assessment tools, along with therapeutic options such as cholinesterase inhibitors, NMDA receptor antagonists, and advanced biologics like anti-amyloid monoclonal antibodies. The increasing global burden of dementia and the growing focus on early-stage diagnosis and disease-modifying therapies are significantly shaping the market landscape.

Market Growth Drivers:

The growth of the global Alzheimer’s disease diagnostics and treatment market is primarily driven by the rising prevalence of dementia and Alzheimer’s disease worldwide, particularly among the aging population. Increasing awareness regarding early diagnosis and the benefits of timely intervention has accelerated demand for advanced diagnostic tools such as blood-based biomarkers and imaging technologies. Continuous advancements in therapeutic approaches, especially the development of anti-amyloid monoclonal antibodies and combination therapies, are further propelling market expansion. Additionally, strong investments in research and development by pharmaceutical and biotechnology companies, along with supportive government initiatives and funding for neurological research, are contributing significantly to market growth.

Market Restraints:

Despite strong growth potential, the Alzheimer’s disease diagnostics and treatment market faces several challenges. High costs associated with advanced diagnostic procedures and innovative biologic treatments limit accessibility, especially in low- and middle-income regions. Moreover, the complexity of Alzheimer’s disease pathology and the historically high failure rate of clinical trials for new drugs create uncertainty in therapeutic development. Limited availability of skilled professionals and infrastructure for early and accurate diagnosis in certain regions also acts as a barrier. Ethical concerns and regulatory hurdles related to novel therapies further complicate market growth.

Market Opportunities:

The market presents substantial opportunities driven by the increasing shift toward early and non-invasive diagnostic solutions, such as blood-based biomarker testing and digital cognitive assessment tools. Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa offer untapped growth potential due to improving healthcare infrastructure and rising awareness of neurological disorders. The growing adoption of personalized medicine and precision therapeutics is expected to open new avenues for targeted Alzheimer’s treatments. Furthermore, collaborations between diagnostic companies, pharmaceutical firms, and research institutions are likely to accelerate innovation and commercialization of next-generation solutions, enhancing overall market prospects.

Key Questions Answered in the Report:

• What are the primary factors driving the global Alzheimer’s disease diagnostics and treatment market's growth?
• Which regions and segments are witnessing the highest demand for diagnostic and therapeutic solutions?
• How are advancements in biomarker technologies and biologic therapies shaping the market?
• Who are the key players in the Alzheimer’s disease diagnostics and treatment market, and what strategies are they adopting?
• What are the emerging trends and future projections for the global market?

Competitive Analysis:

Leading companies in the Alzheimer’s disease diagnostics and treatment market are focusing on innovation, strategic collaborations, and expansion of their product portfolios to strengthen their competitive position. Significant emphasis is being placed on the development of accurate, non-invasive diagnostic tools and disease-modifying therapies. Companies are also investing heavily in clinical trials and regulatory approvals for novel therapeutics, particularly in the biologics segment. Partnerships with healthcare providers, research institutes, and diagnostic laboratories are further helping companies enhance their global footprint and improve accessibility to advanced Alzheimer’s solutions.

Companies Covered in This Report:

• Fujirebio
• Roche Diagnostics
• Cognoptix Inc
• Sysmex Corporation
• PHC Holdings Corporation
• Quest Diagnostics
• C2N Diagnostics
• Araclon Biotech (Grifols, S.A.)
• Quanterix
• Beckman Coulter, Inc.
• Laboratory Corporation of America® Holdings
• Eli Lilly and Company

Market Segmentation

By Solution

• Therapeutics
• Diagnostics

By Sales Channel

• Retail Sales
• Institutional Sales

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Middle East & Africa
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Alzheimer’s Disease Diagnostics & Treatment Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Solution/Service Adoption Analysis
3.2. Disease Epidemiology- Alzheimer
3.3. Recent Solution Launch and Approval Insights
3.4. Clinical Trials- Pipeline Assessment (Drugs)
3.5. Regulatory Landscape
3.6. Reimbursement Scenario
3.7. PESTLE Analysis
3.8. Porter’s Five Force Analysis
3.9. Promotional Strategies, By Key Players
3.10. Value Chain Analysis
3.11. Parent Market Analysis
4. Global Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Alzheimer’s Disease Diagnostics & Treatment Market Outlook: Solution
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Solution, 2019-2024
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
4.3.3.1. Therapeutics
4.3.3.1.1. Cholinesterase Inhibitors
4.3.3.1.2. NMDA Receptor Antagonists
4.3.3.1.3. Manufactured Combinations
4.3.3.1.4. Anti-Amyloid Monoclonal Antibodies
4.3.3.1.5. Others
4.3.3.2. Diagnostics
4.3.3.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
4.3.3.2.2. Blood-based Biomarker Tests
4.3.3.2.3. Computerized Cognitive Tests and Devices
4.3.3.2.4. Brain Imaging Test
4.3.3.2.5. Others
4.3.4. Market Attractiveness Analysis: Solution
4.4. Global Alzheimer’s Disease Diagnostics & Treatment Market Outlook: Sales Channel
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Sales Channel, 2019-2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
4.4.3.1. Retail Sales
4.4.3.1.1. Retail Pharmacies
4.4.3.1.2. Online Pharmacies
4.4.3.2. Institutional Sales
4.4.3.2.1. Diagnostic Centers
4.4.3.2.2. Hospitals
4.4.3.2.3. Specialty Clinics
4.4.3.2.4. Others
4.4.4. Market Attractiveness Analysis: Sales Channel
5. Global Alzheimer’s Disease Diagnostics & Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Solution
6.2.3. By Sales Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
6.4.1. Therapeutics
6.4.1.1. Cholinesterase Inhibitors
6.4.1.2. NMDA Receptor Antagonists
6.4.1.3. Manufactured Combinations
6.4.1.4. Anti-Amyloid Monoclonal Antibodies
6.4.1.5. Others
6.4.2. Diagnostics
6.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
6.4.2.2. Blood-based Biomarker Tests
6.4.2.3. Computerized Cognitive Tests and Devices
6.4.2.4. Brain Imaging Test
6.4.2.5. Others
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
6.5.1. Retail Sales
6.5.1.1. Retail Pharmacies
6.5.1.2. Online Pharmacies
6.5.2. Institutional Sales
6.5.2.1. Diagnostic Centers
6.5.2.2. Hospitals
6.5.2.3. Specialty Clinics
6.5.2.4. Others
6.6. Market Attractiveness Analysis
7. Europe Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Solution
7.2.3. By Sales Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
7.4.1. Therapeutics
7.4.1.1. Cholinesterase Inhibitors
7.4.1.2. NMDA Receptor Antagonists
7.4.1.3. Manufactured Combinations
7.4.1.4. Anti-Amyloid Monoclonal Antibodies
7.4.1.5. Others
7.4.2. Diagnostics
7.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
7.4.2.2. Blood-based Biomarker Tests
7.4.2.3. Computerized Cognitive Tests and Devices
7.4.2.4. Brain Imaging Test
7.4.2.5. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
7.5.1. Retail Sales
7.5.1.1. Retail Pharmacies
7.5.1.2. Online Pharmacies
7.5.2. Institutional Sales
7.5.2.1. Diagnostic Centers
7.5.2.2. Hospitals
7.5.2.3. Specialty Clinics
7.5.2.4. Others
7.6. Market Attractiveness Analysis
8. East Asia Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Solution
8.2.3. By Sales Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
8.4.1. Therapeutics
8.4.1.1. Cholinesterase Inhibitors
8.4.1.2. NMDA Receptor Antagonists
8.4.1.3. Manufactured Combinations
8.4.1.4. Anti-Amyloid Monoclonal Antibodies
8.4.1.5. Others
8.4.2. Diagnostics
8.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
8.4.2.2. Blood-based Biomarker Tests
8.4.2.3. Computerized Cognitive Tests and Devices
8.4.2.4. Brain Imaging Test
8.4.2.5. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
8.5.1. Retail Sales
8.5.1.1. Retail Pharmacies
8.5.1.2. Online Pharmacies
8.5.2. Institutional Sales
8.5.2.1. Diagnostic Centers
8.5.2.2. Hospitals
8.5.2.3. Specialty Clinics
8.5.2.4. Others
8.6. Market Attractiveness Analysis
9. South Asia & Oceania Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Solution
9.2.3. By Sales Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
9.4.1. Therapeutics
9.4.1.1. Cholinesterase Inhibitors
9.4.1.2. NMDA Receptor Antagonists
9.4.1.3. Manufactured Combinations
9.4.1.4. Anti-Amyloid Monoclonal Antibodies
9.4.1.5. Others
9.4.2. Diagnostics
9.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
9.4.2.2. Blood-based Biomarker Tests
9.4.2.3. Computerized Cognitive Tests and Devices
9.4.2.4. Brain Imaging Test
9.4.2.5. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
9.5.1. Retail Sales
9.5.1.1. Retail Pharmacies
9.5.1.2. Online Pharmacies
9.5.2. Institutional Sales
9.5.2.1. Diagnostic Centers
9.5.2.2. Hospitals
9.5.2.3. Specialty Clinics
9.5.2.4. Others
9.6. Market Attractiveness Analysis
10. Latin America Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Solution
10.2.3. By Sales Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
10.4.1. Therapeutics
10.4.1.1. Cholinesterase Inhibitors
10.4.1.2. NMDA Receptor Antagonists
10.4.1.3. Manufactured Combinations
10.4.1.4. Anti-Amyloid Monoclonal Antibodies
10.4.1.5. Others
10.4.2. Diagnostics
10.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
10.4.2.2. Blood-based Biomarker Tests
10.4.2.3. Computerized Cognitive Tests and Devices
10.4.2.4. Brain Imaging Test
10.4.2.5. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
10.5.1. Retail Sales
10.5.1.1. Retail Pharmacies
10.5.1.2. Online Pharmacies
10.5.2. Institutional Sales
10.5.2.1. Diagnostic Centers
10.5.2.2. Hospitals
10.5.2.3. Specialty Clinics
10.5.2.4. Others
10.6. Market Attractiveness Analysis
11. Middle East & Africa Alzheimer’s Disease Diagnostics & Treatment Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Solution
11.2.3. By Sales Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Solution, 2025-2032
11.4.1. Therapeutics
11.4.1.1. Cholinesterase Inhibitors
11.4.1.2. NMDA Receptor Antagonists
11.4.1.3. Manufactured Combinations
11.4.1.4. Anti-Amyloid Monoclonal Antibodies
11.4.1.5. Others
11.4.2. Diagnostics
11.4.2.1. Cerebrospinal Fluid (CSF) Biomarker Tests
11.4.2.2. Blood-based Biomarker Tests
11.4.2.3. Computerized Cognitive Tests and Devices
11.4.2.4. Brain Imaging Test
11.4.2.5. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sales Channel, 2025-2032
11.5.1. Retail Sales
11.5.1.1. Retail Pharmacies
11.5.1.2. Online Pharmacies
11.5.2. Institutional Sales
11.5.2.1. Diagnostic Centers
11.5.2.2. Hospitals
11.5.2.3. Specialty Clinics
11.5.2.4. Others
11.6. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Fujirebio
12.3.1.1. Overview
12.3.1.2. Segments and Solutions
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Roche Diagnostics
12.3.3. Cognoptix Inc
12.3.4. Sysmex Corporation
12.3.5. PHC Holdings Corporation
12.3.6. Quest Diagnostic
12.3.7. C2N Diagnostics
12.3.8. Araclon Biotech (Grifols, S.A.)
12.3.9. Quanterix
12.3.10. Beckman Coulter, Inc.
12.3.11. Laboratory Corporation of America® Holdings
12.3.12. Eli Lilly and Company
12.3.13. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations